| Name | Title | Contact Details |
|---|
At Outpost, we are committed to developing novel therapeutics for the treatment of gastrointestinal and urologic disorders. The company`s lead clinical-stage product candidate is in development for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). Located in Indianapolis and London, Outpost is a private company launched in 2016 with a $61 million Series A venture capital financing from Frazier Healthcare Partners, Adams Street Partners, Novo Holdings A/S, Vivo Capital, and Takeda Ventures.
Founded in 2014, Glyscend is dedicated to the development of a truly revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway.
Logical Therapeutics is a Foxboro, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Zygote is a Lindon, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ganeden Biotech is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.